Tmprss2 specific miRNAs as promising regulators for SARS-CoV-2 entry checkpoint

Kaur, Taruneet; Kapila, Suman; Kapila, Rajeev; Kumar, Sandeep; Upadhyay, Divya; Kaur, Manjeet; Sharma, Chandresh

doi:10.1016/j.virusres.2020.198275

Cited by 30 publications

(30 citation statements)

References 48 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, additional experiments are necessary to elaborate the network. The latest study by Kaur et al [233], published in January 2021, indeed confirms that TMPRSS2 is a new molecular target for SARS-CoV-2 early treatment and prevention (Figure 6). They recognized miR-214, miR-98, and miR-32 with the prospective therapeutic potential to silence the TMPRSS2.…”

Section: Alternative Approachmentioning

confidence: 67%

“…These three miRNAs showed a strong binding affinity to TMPRSS2 with the highest probability of interactions, especially miR-32, whose role was already raised in in vitro studies. However, further and detailed in vivo validations are needed for the ultimate mechanistic functionalities and the comprehensive understanding of the COVID-19 course [233].…”

Section: Alternative Approachmentioning

confidence: 99%

See 1 more Smart Citation

Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy

Narożna

Rubiś

2021

IJMS

View full text Add to dashboard Cite

Recently, we have experienced a serious pandemic. Despite significant technological advances in molecular technologies, it is very challenging to slow down the infection spread. It appeared that due to globalization, SARS-CoV-2 spread easily and adapted to new environments or geographical or weather zones. Additionally, new variants are emerging that show different infection potential and clinical outcomes. On the other hand, we have some experience with other pandemics and some solutions in virus elimination that could be adapted. This is of high importance since, as the latest reports demonstrate, vaccine technology might not follow the new, mutated virus outbreaks. Thus, identification of novel strategies and markers or diagnostic methods is highly necessary. For this reason, we present some of the latest views on SARS-CoV-2/COVID-19 therapeutic strategies and raise a solution based on miRNA. We believe that in the face of the rapidly increasing global situation and based on analogical studies of other viruses, the possibility of using the biological potential of miRNA technology is very promising. It could be used as a promising diagnostic and prognostic factor, as well as a therapeutic target and tool.

show abstract

Section: Alternative Approachmentioning

confidence: 67%

Section: Alternative Approachmentioning

confidence: 99%

Anti-SARS-CoV-2 Strategies and the Potential Role of miRNA in the Assessment of COVID-19 Morbidity, Recurrence, and Therapy

Narożna

Rubiś

2021

IJMS

View full text Add to dashboard Cite

show abstract

“…The use of miRNA targeting the SARS-CoV-2 TMPRSS2 coreceptor to prevent cell entry has also been studied using the Caco-2 cell line. (Kaur et al, 2021) Hu h-7: Huh-7, derived from human colorectal adenocarcinoma, is another popular cell line model that has had uses in multiple areas of viral and drug research. The Huh-7 cell line was found to also exhibit ACE-2 receptor protein expression and so it has been selected in several SARS-CoV-2 studies including investigations of anti-HCV drugs against SARS-CoV-2 (Sacramento et al, 2021), repurposing of viral inhibitors (Puhl et al, 2021), testing of an immunomodulating herbal extract (Roshdy et al, 2020) and traditional Chinese medicine effect on signaling pathways involved in SARS-CoV-2 pathogenesis (Ma et al, 2020).…”

Section: In Vitro Models Of Sars-cov-2 Infectionmentioning

confidence: 99%

Experimental Models of COVID-19

Caldera-Crespo

Paidas

Roy

et al. 2022

Front. Cell. Infect. Microbiol.

View full text Add to dashboard Cite

COVID-19 is the most consequential pandemic of the 21st century. Since the earliest stage of the 2019-2020 epidemic, animal models have been useful in understanding the etiopathogenesis of SARS-CoV-2 infection and rapid development of vaccines/drugs to prevent, treat or eradicate SARS-CoV-2 infection. Early SARS-CoV-1 research using immortalized in-vitro cell lines have aided in understanding different cells and receptors needed for SARS-CoV-2 infection and, due to their ability to be easily manipulated, continue to broaden our understanding of COVID-19 disease in in-vivo models. The scientific community determined animal models as the most useful models which could demonstrate viral infection, replication, transmission, and spectrum of illness as seen in human populations. Until now, there have not been well-described animal models of SARS-CoV-2 infection although transgenic mouse models (i.e. mice with humanized ACE2 receptors with humanized receptors) have been proposed. Additionally, there are only limited facilities (Biosafety level 3 laboratories) available to contribute research to aid in eventually exterminating SARS-CoV-2 infection around the world. This review summarizes the most successful animal models of SARS-CoV-2 infection including studies in Non-Human Primates (NHPs) which were found to be susceptible to infection and transmitted the virus similarly to humans (e.g., Rhesus macaques, Cynomolgus, and African Green Monkeys), and animal models that do not require Biosafety level 3 laboratories (e.g., Mouse Hepatitis Virus models of COVID-19, Ferret model, Syrian Hamster model). Balancing safety, mimicking human COVID-19 and robustness of the animal model, the Murine Hepatitis Virus-1 Murine model currently represents the most optimal model for SARS-CoV-2/COVID19 research. Exploring future animal models will aid researchers/scientists in discovering the mechanisms of SARS-CoV-2 infection and in identifying therapies to prevent or treat COVID-19.

show abstract

“…Subsequently, another study forecasted that hsa-miR-32, hsa-miR-98, and hsa-miR-214 can silence the expression of TMPRSS2 and might pave a way to continue exploring the possible therapeutic roles of hsa-miR-32, hsa-miR-98, and hsa-miR-214 against SARS-CoV-2 in vivo and in vitro . Interestingly, in this same investigation, hsa-miR-32 was demonstrated to silence the expression of TMPRSS2 in Caco-2 cells significantly, and hence upcoming research should be focused on this miRNA ( Kaur et al, 2021 ). Nevertheless, it would also be worth exploring if miRNAs could inhibit the production of the structural and non-structural proteins that participate in crucial steps of the life cycle of SARS-CoV-2, such as S protein, envelope (E) protein, Nsp1, Nsp4, and Nsp12 ( Yadav et al, 2021 ).…”

Section: Future Perspectivesmentioning

confidence: 69%